Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases
Seminars in Arthritis and Rheumatism,  Clinical Article

Perez-Alvarez R et al. – The authors found that 97% of cases of ILD associated with biologic agents were associated with agents blocking tumor necrosis factor-α, a cytokine that has been implicated in the pathophysiology of pulmonary fibrosis. Drug-induced ILD had a poor prognosis, with an overall mortality rate of around one third, rising to two thirds in patients with preexisting ILD

Methods

  • In 2006, Study Group on Autoimmune Diseases of Spanish Society of Internal Medicine created BIOGEAS project
  • One objective was to collect data on autoimmune diseases secondary to use of biologic agents by quarterly Medline search surveillance of reported cases
  • Baseline included articles published between January 1990 and March 2010, including MeSH term “lung diseases, interstitial” as key research term
  • Report an unpublished case of ILD secondary to biologic therapy

Results
  • 122 reported cases of new-onset or exacerbation of ILD secondary to administration of biologic therapies
  • Biologic agents associated with ILD overwhelmingly anti-tumor necrosis factor agents (etanercept in 58 cases and infliximab in 56) and administered for RA in 108 (89%) patients
  • ILD appeared mean of 26 weeks after initiation of biologic agents
  • ILD confirmed by pulmonary biopsy in 26 cases, although specific histopathologic description detailed in only 20: 7 patients classified as usual interstitial pneumonia, 6 as nonspecific interstitial pneumonia, 5 as organizing pneumonia, 1 as diffuse alveolar damage, and 1 as lymphoid interstitial pneumonia
  • Treatment of ILD included withdrawal of biologic agents in all cases but 1
  • The outcome of ILD was detailed in 52 cases
  • Complete resolution reported in 21 (40%) cases, improvement or partial resolution in 13 (25%), and no resolution in 18 (35%)
  • 15 (29%) patients died during follow-up, majority (70%) during first 5 weeks after initiating biologic therapy
  • In comparison with survivors, patients who died were aged >65 years (67% vs 33%, P = 0.036), with later onset of ILD (46 weeks vs 15 weeks, P = 0.006)
  • Received immunosuppressive drugs more frequently (33% vs 8%, P = 0.036), and more often had a previous diagnosis of ILD (67% vs 29%, P = 0.025)

Please login or register to follow this author.
Are you sure you want to Unfollow this Author?
► Click here to access PubMed, Publisher and related articles...
<< Previous Article | Next Article >>

    Currently, there are no available articles.

Your Unread Messages in Rheumatology

See All >> Messages include industry-sponsored communications and special communications from MDLinx

Most Popular Rheumatology Articles

Indexed Journals in Rheumatology: Arthritis & Rheumatism, Annals of Rheumatic Diseases, Journal of Rheumatologymore

Register now to view all the MDLinx contents (FREE)!

  • Stay current on the latest literature, research and clinical news
  • Get special communications and offers from MDLinx and our sponsors
  • Receive invitations to paid market research
View Samples and Register

Connect with us, stay current.

Receive the latest mecial news
updates for free via email

Sign up!

Subscribe to our free RSS feeds:

Get the latest news in your specialty automatically added to your newsreader or your personal My Yahoo!, Google, My MSN or My AOL page. Learn More

Close